(0.13%) 5 138.25 points
(0.10%) 38 478 points
(0.21%) 17 883 points
(-0.24%) $83.65
(1.72%) $1.956
(0.13%) $2 350.30
(0.45%) $27.66
(1.60%) $936.85
(-0.17%) $0.933
(-0.27%) $10.99
(-0.29%) $0.798
(1.19%) $92.97
@ $17.66
発行日: 15 2月 2024 @ 03:37
リターン: -6.17%
前回のシグナル: 2月 15 - 02:03
前回のシグナル:
リターン: 1.15 %
Live Chart Being Loaded With Signals
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access...
Stats | |
---|---|
本日の出来高 | 321 644 |
平均出来高 | 527 866 |
時価総額 | 2.65B |
EPS | $0 ( 2024-02-29 ) |
次の収益日 | ( $0.100 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -47.34 |
ATR14 | $0.0120 (0.07%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Feehery William F | Buy | 124 779 | Restricted Stock Units |
2024-04-02 | Smith Patrick F | Sell | 5 264 | Common Stock |
2024-04-02 | Smith Patrick F | Sell | 649 | Common Stock |
2024-04-02 | Smith Patrick F | Sell | 3 024 | Common Stock |
2024-04-02 | Smith Patrick F | Sell | 328 | Common Stock |
INSIDER POWER |
---|
30.50 |
Last 100 transactions |
Buy: 798 344 | Sell: 442 671 |
ボリューム 相関
Certara, Inc. 相関
10 最も負の相関 | |
---|---|
GOOD | -0.959 |
CSSEP | -0.958 |
HALO | -0.955 |
CBNK | -0.952 |
SFST | -0.947 |
WASH | -0.947 |
WTBA | -0.946 |
MCBS | -0.946 |
UTHR | -0.946 |
BMRA | -0.945 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Certara, Inc. 相関 - 通貨/商品
Certara, Inc. 財務諸表
Annual | 2023 |
収益: | $354.34M |
総利益: | $167.79M (47.35 %) |
EPS: | $-0.350 |
FY | 2023 |
収益: | $354.34M |
総利益: | $167.79M (47.35 %) |
EPS: | $-0.350 |
FY | 2022 |
収益: | $335.64M |
総利益: | $203.07M (60.50 %) |
EPS: | $0.0939 |
FY | 2021 |
収益: | $286.10M |
総利益: | $174.49M (60.99 %) |
EPS: | $-0.0900 |
Financial Reports:
No articles found.
Certara, Inc.
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。